Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.
Comprehensive, easy-to-understand information about this condition
How we create this content →Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
The documentation on autoimmune hepatitis is limited due to its relatively low prevalence, which restricts the scope of systematic clinical studies. Additionally, the complexity of autoimmune diseases often leads to overlapping symptoms with other conditions, making characterization challenging. As research continues, more information may become available, offering hope for better understanding and management.
To navigate your care effectively, consider seeking a hepatologist or a gastroenterologist with expertise in autoimmune liver diseases. Engaging with the Autoimmune Hepatitis Association (AIHA) can provide valuable resources and support. You may also explore participation in clinical trials, which can offer access to emerging therapies. For further assistance, the National Organization for Rare Disorders (NORD) can be a helpful resource. Their website is rarediseases.org.
There are currently 31 active clinical trials investigating various aspects of autoimmune hepatitis. Notably, several orphan drugs are in development, including budesonide, cannabidiol, naltrexone, and Synthetic PreImplantation Factor. These treatments aim to improve management and outcomes for patients. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for autoimmune hepatitis.
Actionable guidance for navigating care for autoimmune hepatitis
To navigate your care effectively, consider seeking a hepatologist or a gastroenterologist with expertise in autoimmune liver diseases. Engaging with the Autoimmune Hepatitis Association (AIHA) can provide valuable resources and support. You may also explore participation in clinical trials, which can offer access to emerging therapies. For further assistance, the National Organization for Rare Disorders (NORD) can be a helpful resource. Their website is rarediseases.org.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the autoimmune hepatitis community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 1, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning autoimmune hepatitis
Updated Jun 25, 2007
The CDC's Advisory Committee on Immunization Practices will meet on June 27-28, 2007, to discuss Hepatitis A vaccine prophylaxis. This meeting is part of ongoing efforts to enhance vaccination strategies.
Acute viral hepatitis cases, specifically hepatitis A, B, and C, have significantly declined in the U.S. from 1995 to 2005, with hepatitis A and B reaching their lowest levels. This trend highlights the effectiveness of public health initiatives in managing these diseases.